CL2019002056A1 - Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650) - Google Patents

Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650)

Info

Publication number
CL2019002056A1
CL2019002056A1 CL2019002056A CL2019002056A CL2019002056A1 CL 2019002056 A1 CL2019002056 A1 CL 2019002056A1 CL 2019002056 A CL2019002056 A CL 2019002056A CL 2019002056 A CL2019002056 A CL 2019002056A CL 2019002056 A1 CL2019002056 A1 CL 2019002056A1
Authority
CL
Chile
Prior art keywords
polypeptide
lukd
leukocidin
treatment
staphylococcus aureus
Prior art date
Application number
CL2019002056A
Other languages
English (en)
Inventor
Victor J Torres
Francis Alonzo
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Publication of CL2019002056A1 publication Critical patent/CL2019002056A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A MÉTODOS Y COMPOSICIONES PARA LA PREVENCIÓN Y EL TRATAMIENTO DE STAPHYLOCOCCUS AUREUS EN UN SUJETO. LAS COMPOSICIONES TERAPÉUTICAS DE LA PRESCITO INVENCIÓN COMPRENDEN PROTEÍNAS O POLIPÉPTIDOS DE LEUCOCIDINA E Y/O D Y ANTICUERPOS ANTI-LEUCOCIDINA E Y/O D. LA INVENCIÓN SE REFIERE ADEMÁS A MÉTODOS PARA IDENTIFICAR INHIBIDORES DE CITOTOXICIDAD DE LUKE/D E INHIBIDORES DE UNIÓN DE LUKE/D A LEUCOCITOS.
CL2019002056A 2011-06-19 2019-07-23 Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650) CL2019002056A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161498596P 2011-06-19 2011-06-19

Publications (1)

Publication Number Publication Date
CL2019002056A1 true CL2019002056A1 (es) 2019-11-29

Family

ID=47423177

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013003650A CL2013003650A1 (es) 2011-06-19 2013-12-19 Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo anti leucocidina luke y un portador farmaceuticamente aceptable.
CL2019002056A CL2019002056A1 (es) 2011-06-19 2019-07-23 Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2013003650A CL2013003650A1 (es) 2011-06-19 2013-12-19 Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo anti leucocidina luke y un portador farmaceuticamente aceptable.

Country Status (20)

Country Link
US (7) US9091689B2 (es)
EP (3) EP3403669B1 (es)
JP (4) JP6170913B2 (es)
KR (1) KR102050267B1 (es)
CN (3) CN103717234A (es)
AU (1) AU2012273123C1 (es)
BR (2) BR112013032774B1 (es)
CA (1) CA2839554C (es)
CL (2) CL2013003650A1 (es)
DK (1) DK3403669T3 (es)
ES (2) ES2812181T3 (es)
HR (1) HRP20201265T1 (es)
HU (1) HUE051832T2 (es)
IL (2) IL229922B (es)
LT (1) LT3403669T (es)
MX (2) MX340446B (es)
NZ (1) NZ764564A (es)
RU (1) RU2635462C2 (es)
SI (1) SI3403669T1 (es)
WO (1) WO2012177658A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103717234A (zh) * 2011-06-19 2014-04-09 纽约大学 治疗和预防金黄色葡萄球菌感染及相关病状的方法
CN104428000A (zh) 2012-05-02 2015-03-18 纽约大学 治疗和预防金黄色葡萄球菌感染和相关病状的方法
US10301378B2 (en) * 2013-06-18 2019-05-28 New York University Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets
CA2925071A1 (en) * 2013-10-17 2015-04-23 Arsanis Biosciences Gmbh Cross-reactive staphylococcus aureus antibody sequences
JP2017502002A (ja) * 2013-12-09 2017-01-19 ニューヨーク・ユニバーシティ 抗ブドウ球菌剤の食細胞送達用組成物及び方法
BE1022875B1 (fr) * 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus
EP3180620B1 (en) * 2014-08-12 2020-01-01 X4 Pharmaceuticals (Austria) GmbH Predicting s. aureus disease
JP2018513168A (ja) * 2015-04-17 2018-05-24 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 抗スタフィロコッカス・アウレウス抗体組み合わせ製剤
JP2018517708A (ja) * 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
CN105641689A (zh) * 2016-01-21 2016-06-08 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌β-溶血素亚单位疫苗的制备方法及应用
EP3464349A4 (en) 2016-05-23 2020-08-26 New York University COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS
AU2017346974B2 (en) 2016-10-21 2022-03-31 Socpra Sciences Et Génie S.E.C. Vaccine constructs and uses thereof against staphylococcus infections
EP3582683A4 (en) * 2017-02-20 2021-03-17 The Regents of The University of California SEROLOGICAL TEST FOR SILENT BRAIN ISEMIA
CN107224575B (zh) * 2017-03-06 2018-11-09 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用
CN106749652A (zh) * 2017-03-14 2017-05-31 天津喜诺生物医药有限公司 一种金黄色葡萄球菌肽聚糖的多克隆抗体
WO2020023644A2 (en) 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
BR112021016996A8 (pt) * 2019-02-28 2022-11-22 Dandi Bioscience Inc Polipeptídeo com atividade antibacteriana, composição para prevenir ou tratar sepsis compreendendo a mesma e composição antibacteriana
CN111423516B (zh) * 2020-04-01 2022-02-11 广州佰斯伦医疗器械有限公司 一种蛋白及其在创口修复及抑菌中的应用
CN111398194B (zh) * 2020-04-10 2020-11-03 上海华茂药业有限公司 一种用于测定艾考糊精中肽聚糖的方法
CN112851770B (zh) * 2021-02-05 2022-10-04 中国人民解放军陆军军医大学 一种用于诊断或防治金黄色葡萄球菌感染的α溶血素抗原表位肽及其应用
CN114317787A (zh) * 2021-12-29 2022-04-12 成都大学 吸附磁珠及其试剂盒和用途以及检测金黄色葡萄球菌的方法
CN115991766A (zh) * 2023-03-13 2023-04-21 广州美健生物技术有限公司 一种细菌抗原检测试剂盒及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2344166C (en) 1998-09-14 2008-11-18 Nabi Compositions of .beta.-glucans and specific igiv
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2002077183A2 (en) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
US20030171563A1 (en) 2001-05-18 2003-09-11 Mcnamara Peter J. Regulators of bacterial virulence factor expression
WO2004069833A1 (ja) 2003-02-07 2004-08-19 Takeda Pharmaceutical Company Limited 縮環ピリジン誘導体、その製造法および用途
IL157398A0 (en) 2003-08-14 2004-02-19 Hadasit Med Res Service Pharmaceutical compositions comprising ccr5 antagonists
US7622125B2 (en) 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
BRPI0515516B1 (pt) * 2004-09-22 2017-08-08 Glaxosmithkline Biologicals S.A. Immunogenic composition, vaccine, method of manufacturing a vaccine, and, use of immunogenic composition.
WO2007062150A2 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Leukotoxin compositions and therapeutic methods
WO2007095347A2 (en) 2006-02-13 2007-08-23 The Gov. Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Methods and compositions related to ghs-r antagonists
BRPI0712843A2 (pt) 2006-06-12 2012-07-31 Pfizer Prod Inc antagonista de ccr5 e seus usos
TW200744632A (en) * 2006-06-12 2007-12-16 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
JP2008013447A (ja) * 2006-07-03 2008-01-24 Juntendo 毒素検出方法
JP2010519216A (ja) 2007-02-15 2010-06-03 ファイザー・リミテッド Ｃｃｒ５拮抗薬のための医薬組成物および方法
EP2411038B1 (en) 2009-03-27 2016-12-28 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
SI2510947T1 (sl) * 2009-04-14 2016-05-31 Glaxosmithkline Biologicals S.A. Sestavki za imunizacijo proti Staphylococcus aureus
US8409584B2 (en) * 2009-05-05 2013-04-02 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
EP2488198B1 (en) 2009-10-13 2016-09-28 Rutgers, the State University of New Jersey Treatment and diagnosis of autoimmune disorders
US9783582B2 (en) * 2010-05-05 2017-10-10 New York University Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
CN103717234A (zh) * 2011-06-19 2014-04-09 纽约大学 治疗和预防金黄色葡萄球菌感染及相关病状的方法
BR112013032911A2 (pt) * 2011-06-19 2017-01-24 Univ New York leucotoxina e/d como um novo agente anti-inflamatório e microbicida

Also Published As

Publication number Publication date
NZ764564A (en) 2022-10-28
JP6170913B2 (ja) 2017-07-26
NZ619938A (en) 2016-03-31
EP3403669B1 (en) 2020-07-15
ES2684088T3 (es) 2018-10-01
WO2012177658A3 (en) 2013-02-21
RU2635462C2 (ru) 2017-11-13
JP6452765B2 (ja) 2019-01-16
CA2839554C (en) 2023-09-26
AU2012273123A1 (en) 2014-01-16
MX2013014640A (es) 2014-05-14
BR112013032774A2 (pt) 2017-01-31
NZ710439A (en) 2017-04-28
AU2012273123B2 (en) 2018-01-04
JP6758363B2 (ja) 2020-09-23
US20170008953A1 (en) 2017-01-12
DK3403669T3 (da) 2020-08-24
EP3777885A1 (en) 2021-02-17
AU2012273123C1 (en) 2018-08-09
JP2019034976A (ja) 2019-03-07
CL2013003650A1 (es) 2014-09-26
US20190135900A1 (en) 2019-05-09
KR20140039294A (ko) 2014-04-01
EP2720714A2 (en) 2014-04-23
US20150274814A1 (en) 2015-10-01
BR122020000047B1 (pt) 2021-04-13
SI3403669T1 (sl) 2020-11-30
CN109893644A (zh) 2019-06-18
IL258886A (en) 2018-06-28
US20130017203A1 (en) 2013-01-17
US11078258B2 (en) 2021-08-03
US20200392211A1 (en) 2020-12-17
US10202440B2 (en) 2019-02-12
JP2020193225A (ja) 2020-12-03
ES2812181T3 (es) 2021-03-16
CA2839554A1 (en) 2012-12-27
WO2012177658A2 (en) 2012-12-27
JP7129451B2 (ja) 2022-09-01
HRP20201265T1 (hr) 2021-02-19
CN103717234A (zh) 2014-04-09
CN104474531A (zh) 2015-04-01
RU2014101488A (ru) 2015-07-27
JP2017214397A (ja) 2017-12-07
US9091689B2 (en) 2015-07-28
MX340446B (es) 2016-07-08
US9783597B2 (en) 2017-10-10
US10669329B2 (en) 2020-06-02
EP3403669A1 (en) 2018-11-21
KR102050267B1 (ko) 2019-11-29
IL229922B (en) 2018-05-31
US20210340228A1 (en) 2021-11-04
LT3403669T (lt) 2020-10-12
US9481723B2 (en) 2016-11-01
EP2720714A4 (en) 2015-01-14
MX357938B (es) 2018-07-31
HUE051832T2 (hu) 2021-03-29
NZ730359A (en) 2020-05-29
BR112013032774B1 (pt) 2020-05-05
JP2014520149A (ja) 2014-08-21
US20180057571A1 (en) 2018-03-01
EP2720714B1 (en) 2018-07-18
WO2012177658A8 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
CL2019002056A1 (es) Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650)
DOP2019000201A (es) Compuestos inhibidores del vih
CO2018006299A2 (es) Compuestos novedosos
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
GT201100181A (es) "inhibidores de proteina cinasa"
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
EA201791168A1 (ru) Способы и составы для лечения сосудистых заболеваний глаз
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
BR112012019098A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer e anticorpo
CR20140036A (es) Compuesto inhibidor de la señalización de la trayectoria notch
SV2018005621A (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
EA201500265A1 (ru) Ингибиторы репликации вирусов гриппа
EA201692285A1 (ru) Ингибиторы ezh2 для лечения лимфомы
BR112014012607A2 (pt) métodos de tratamento usando um inibidor de interferon gama
UA118255C2 (uk) Композиція, яка містить антитіло до cd38 і леналідомід
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
ECSP13012913A (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
AR101740A1 (es) Terapia de combinación y composiciones
CR20140527A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
AR111697A2 (es) Composición oftálmica para el tratamiento de las alergias oculares
BR112014004065A2 (pt) micro-organismos carregando um antígeno de tumor